
Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.

Expert retina specialists discuss recent developments in the treatment landscape for geographic atrophy (GA) and the future management of patients with coexisting neovascular AMD and GA.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their perspectives on biosimilars in the treatment of neovascular AMD and DME, emphasizing how their cost will affect their uptake.

Adrienne Scott, MD, and Prethy Rao, MD, MPH, discuss implementation of step therapy in neovascular age-related macular degeneration and diabetic macular edema without compromising vision outcomes.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

Expert retina specialists discuss the OPT-302 study and the challenges presented when using 2 agents in tandem to treat diabetic macular edema.

Retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao comment on loading dose recommendations for faricimab or other anti-VEGF therapies in the treatment of DME.

Retina experts discuss the benefits of using intraocular steroids to treat patients with DME as well as their approach to switching to steroids after a poor response to anti-VEGF therapy.

Expert retina specialists provide an overview of the YOSEMITE and RHINE clinical studies of faricimab in the treatment of DME.

Carl Regillo, MD, FACS, FASRS, and Prethy Rao, MD, MPH, discuss the phase 3 trials of faricimab in the treatment of DME and highlighting the enhanced resolution of intraocular fluid.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, review the challenges presented in the management of DME, including the disease burden on the patient.

Retina experts discuss biomarkers to track disease progression in neovascular AMD, as well as their thoughts on the utility of optical coherence tomography angiography (OCT-A).

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Expert retina specialists review the safety profile of faricimab compared with other anti-VEGF therapies in AMD.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, discuss patient selection for faricimab in neovascular AMD, as well as approaches to switching to faricimab after a poor response to other treatment.

Expert retina specialists discuss the use of faricimab and dosing for the treatment of neovascular age-related macular degeneration in the clinical practice setting.

Drs Nathan Steinle, Adrienne Scott, and Carl Regillo comment on the phase 3 trial outcomes of faricimab in neovascular AMD.

Retina experts discuss treatment of wet AMD, focusing on frequency of treatment and treatment breaks, and fluid tolerance.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, provide an overview of the effect of anti-VEGF treatment in neovascular age-related macular degeneration and diabetic macular edema.

Published: July 14th 2023 | Updated:

Published: July 14th 2023 | Updated: